美国FDA于2015年12月21日批准由Actelion Pharmaceuticals US,Inc.公司生产的Uptravi(selexipag)片剂用于治疗成人肺动脉高压(pulmonary arterial hypertension,PAH),并授予孤儿药地位。肺动脉高压是一种罕见的慢性进行性肺病,患者通常身体衰弱,其后果是需进行肺移植或者导致死亡。肺动脉高压同时也是一种高血压病,连接心脏和肺的肺动脉内血压过高,导致心脏右侧负荷过大,引起患者气短、日常 FDA on December 21, 2015 approved Uptravi (selexipag) tablets manufactured by Actelion Pharmaceuticals US, Inc. for the treatment of pulmonary arterial hypertension (PAH) in adults and granted orphan drug status. Pulmonary hypertension is a rare chronic progressive lung disease in which patients are often debilitated, with the consequence of a lung transplant or death. Pulmonary hypertension is also a form of hypertension, and the blood pressure in the pulmonary arteries that connect the heart and lungs is too high, resulting in an excessive load on the right side of the heart, causing shortness of breath and daily